Valid Ghana · FDA Ghana

BENOX EYE DROPS (Each drop contains: Benoxinate Hydrochloride 0.4%w/v)

Benoxinate Hydrochloride

FDA/SD.243-040559 EYE DROPS 0.4%w/v dermatologicals INN generic

What it does

Benoxinate is a medication used to numb the surface of the eye.

Commonly used for: eye discomfort, corneal abrasion (scratch on the eye), ophthalmic procedures

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
FDA/SD.243-040559
Registration date
2024-04-03
Expiry date
2027-05-01
Status
Valid
Active ingredient
Benoxinate Hydrochloride
Dosage form
EYE DROPS
Strength
0.4%w/v
Pack size
-
Therapeutic class
-
ATC class (WHO)
D04AB - Anesthetics for topical use
Drug group
DERMATOLOGICALS
RxNorm RxCUI
18889
Manufacturer / MAH
Egyptian International Pharmaceutical Industries
Applicant / LTR
Renie Chemist Limited - P.O Box An 15794 Accra-North
Country of origin
Egypt
Manufacturer location
شارع الحورية، 10th of Ramadan City 1, Al-Sharqia Governorate 7062831, Egypt

Source: Food and Drugs Authority · fetched 2026-04-18 08:38:20 · updated 2026-10-20 04:00:06

Disclaimer: This information is sourced from Food and Drugs Authority (Ghana). Always consult a qualified healthcare professional before using any medication.

About this medicine

Benoxinate is a medication used to numb the surface of the eye.

What it treats

  • eye discomfort
  • corneal abrasion (scratch on the eye)
  • ophthalmic procedures

How it works

Benoxinate works by blocking nerve signals in the area it is applied, which helps reduce sensation and pain.

Who it's for

Benoxinate is suitable for adults and children needing relief from eye discomfort or undergoing eye examinations.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: benoxinate

BNF-referenced

Benoxinate is a local anaesthetic, primarily used for surface anaesthesia in ophthalmic procedures. It is known for its fast onset and relatively longer duration of action compared to other local anaesthetics. Its chemical structure allows it to effectively block nerve impulses, providing temporary loss of sensation in targeted areas.

Indications

  • Ophthalmic procedures requiring surface anaesthesia
  • Diagnostic procedures in the eye
  • Minor surgical interventions in the eye

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines in paediatric patients.

Adults: Refer to the BNF for specific dosing recommendations based on the procedure and formulation used.

Mechanism of action

Benoxinate binds to sodium channels in the neuronal membrane, stabilizing it and decreasing its permeability to sodium ions. This action inhibits depolarization and effectively blocks the initiation and conduction of nerve impulses, resulting in local anaesthesia.

Pharmacodynamics

As a local anaesthetic, benoxinate is less irritating than tetracaine, making it suitable for sensitive applications such as ocular procedures. Its onset and duration of action are comparable to those of tetracaine, providing effective anaesthesia for minor surgical and diagnostic procedures.

Pharmacokinetics

Benoxinate is absorbed locally at the site of application. It exhibits rapid onset of action, typically within minutes, and its effects can last from 30 minutes to a few hours depending on the concentration used and the site of administration. Metabolism and excretion details are less defined, but local anaesthetics are generally metabolized in the liver and excreted in the urine.

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether benoxinate is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store at room temperature, protected from light. Do not freeze.

Formulations

  • Eye drops
PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: benoxinate

PubChem CID 4633

Molecular formula: C17H28N2O3

Mechanism of action

Oxybuprocaine binds to sodium channel and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions. Depolarization of the neuronal membrane is inhibited thereby blocking the initiation and conduction of nerve impulses.

Pharmacodynamics

Oxybuprocaine is a local anaesthetic. It may be less irritating than tetracaine, and the onset and duration of action are similar to tetracaine.

Biological pathways

Oxybuprocaine Action Pathway PathBank

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.